Compare · BLI vs PRDS
BLI vs PRDS
Side-by-side comparison of Berkeley Lights Inc. (BLI) and Pardes Biosciences Inc. (PRDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLI and PRDS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BLI has more recent analyst coverage (13 ratings vs 3 for PRDS).
- Company
- Berkeley Lights Inc.
- Pardes Biosciences Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 13
- 3
Berkeley Lights Inc.
Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.
Pardes Biosciences Inc.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Latest BLI
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)
- SEC Form 15-12G filed by Berkeley Lights Inc.
- Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hopfield Jessica returned 105,207 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Joshi Mehul returned 65,013 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hobbs Eric returned 244,816 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Moritz Michael J returned 1,451,925 shares to the company (SEC Form 4)
Latest PRDS
- SEC Form 15-12G filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
- SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
- SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
- SEC Form 4: Varney Michael David closing all direct ownership in the company
- SEC Form 4 filed by Smaldone Alsup Laurie
- SEC Form 4 filed by Pottage John C Jr
- SEC Form 4: Lopatin Uri A closing all direct ownership in the company